What Is Happening With Innate Pharma Stock On Friday?_老虎社区_美港股上老虎

What Is Happening With Innate Pharma Stock On Friday?

Benzinga2021-09-18

Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

102

Troytan
·2021-09-19
Good news for Innate Pharma investors
回复
4
举报
SimonTan91
·2021-09-18
Ok
回复
2
举报
JayChou学投资
·2021-09-18
.
回复
5
举报
Rickyt089
·2021-09-18
Like pls
回复
3
举报
收起
- SSVC:
  Ok
  2021-09-19
  回复
  举报
- Geoz88:
  OK
  2021-09-19
  回复
  举报
- SSVC:
  [Strong][ShakeHands]
  2021-09-20
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2168575701?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-18 06:10","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2168575701","market":"us","top_or_hot":-1,"title":"What Is Happening With Innate Pharma Stock On Friday?","media":"Benzinga","content":"<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is Happening With Innate Pharma Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is Happening With Innate Pharma Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html","article_id":"2168575701","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2168575701","pubTimestamp":1631916641,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (N","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康","IPHA":"Innate Pharma SA"},"translate_title":"周五先天制药的股票发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"IPHA":0.9},"content_text":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.\nThe trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).\nAfter a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.\nThe 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.\nThe confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).\nAstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.\nAlso, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.\nEarlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.\nThe analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.\nPrice Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.\n\nLatest Ratings for IPHA\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nSep 2021\nSVB Leerink\nMaintains\n\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":887342831,"gmtCreate":1631984502723,"gmtModify":1632804962943,"author":{"id":"3571482048865852","authorId":"3571482048865852","name":"Troytan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Good news for Innate Pharma investors","listText":"Good news for Innate Pharma investors","text":"Good news for Innate Pharma investors","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/887342831","repostId":2168575701,"repostType":4,"repost":{"id":"2168575701","pubTimestamp":1631916641,"share":"https://www.laohu8.com/m/news/2168575701?lang=&edition=full","pubTime":"2021-09-18 06:10","market":"us","language":"en","title":"What Is Happening With Innate Pharma Stock On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2168575701","media":"Benzinga","summary":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (N","content":"<ul>\n <li><b><a href=\"https://laohu8.com/S/IPHA\">Innate Pharma SA</a>&nbsp;</b>(NASDAQ: IPHA) stock is trading at a 52-week high as its partner&nbsp;<b>AstraZeneca Plc</b>&nbsp;(NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (<i>ESMO21</i>) Congress 2021.</li>\n <li>The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).</li>\n <li>After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab&nbsp;reduced the risk of disease progression or death by 56%&nbsp;(hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.</li>\n <li>The 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.</li>\n <li>The confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).</li>\n <li>AstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.</li>\n <li>Also, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.</li>\n <li>Earlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.</li>\n <li>The analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.</li>\n <li><b>Price Action:</b>&nbsp;IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.</li>\n</ul>\n<p>Latest Ratings for IPHA</p>\n<table>\n <tbody>\n  <tr>\n   <th>Date</th>\n   <th>Firm</th>\n   <th>Action</th>\n   <th>From</th>\n   <th>To</th>\n  </tr>\n </tbody>\n <tbody>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Maintains</td>\n   <td></td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n </tbody>\n</table>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is Happening With Innate Pharma Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is Happening With Innate Pharma Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPHA":"Innate Pharma SA","AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2168575701","content_text":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.\nThe trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).\nAfter a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.\nThe 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.\nThe confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).\nAstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.\nAlso, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.\nEarlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.\nThe analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.\nPrice Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.\n\nLatest Ratings for IPHA\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nSep 2021\nSVB Leerink\nMaintains\n\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":887983678,"gmtCreate":1631958018894,"gmtModify":1632805083564,"author":{"id":"3581989576547489","authorId":"3581989576547489","name":"SimonTan91","avatar":"https://static.tigerbbs.com/33a746662324e75f8c65f010f1588b16","vip":1,"crmLevel":8,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/887983678","repostId":2168575701,"repostType":4,"repost":{"id":"2168575701","pubTimestamp":1631916641,"share":"https://www.laohu8.com/m/news/2168575701?lang=&edition=full","pubTime":"2021-09-18 06:10","market":"us","language":"en","title":"What Is Happening With Innate Pharma Stock On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2168575701","media":"Benzinga","summary":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (N","content":"<ul>\n <li><b><a href=\"https://laohu8.com/S/IPHA\">Innate Pharma SA</a>&nbsp;</b>(NASDAQ: IPHA) stock is trading at a 52-week high as its partner&nbsp;<b>AstraZeneca Plc</b>&nbsp;(NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (<i>ESMO21</i>) Congress 2021.</li>\n <li>The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).</li>\n <li>After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab&nbsp;reduced the risk of disease progression or death by 56%&nbsp;(hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.</li>\n <li>The 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.</li>\n <li>The confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).</li>\n <li>AstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.</li>\n <li>Also, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.</li>\n <li>Earlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.</li>\n <li>The analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.</li>\n <li><b>Price Action:</b>&nbsp;IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.</li>\n</ul>\n<p>Latest Ratings for IPHA</p>\n<table>\n <tbody>\n  <tr>\n   <th>Date</th>\n   <th>Firm</th>\n   <th>Action</th>\n   <th>From</th>\n   <th>To</th>\n  </tr>\n </tbody>\n <tbody>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Maintains</td>\n   <td></td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n </tbody>\n</table>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is Happening With Innate Pharma Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is Happening With Innate Pharma Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPHA":"Innate Pharma SA","AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2168575701","content_text":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.\nThe trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).\nAfter a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.\nThe 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.\nThe confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).\nAstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.\nAlso, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.\nEarlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.\nThe analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.\nPrice Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.\n\nLatest Ratings for IPHA\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nSep 2021\nSVB Leerink\nMaintains\n\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":887918126,"gmtCreate":1631956843765,"gmtModify":1632805087248,"author":{"id":"4091284646222870","authorId":"4091284646222870","name":"JayChou学投资","avatar":"https://static.tigerbbs.com/5bd8491c971437a5db7fb0829fdee4c4","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/887918126","repostId":2168575701,"repostType":4,"repost":{"id":"2168575701","pubTimestamp":1631916641,"share":"https://www.laohu8.com/m/news/2168575701?lang=&edition=full","pubTime":"2021-09-18 06:10","market":"us","language":"en","title":"What Is Happening With Innate Pharma Stock On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2168575701","media":"Benzinga","summary":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (N","content":"<ul>\n <li><b><a href=\"https://laohu8.com/S/IPHA\">Innate Pharma SA</a>&nbsp;</b>(NASDAQ: IPHA) stock is trading at a 52-week high as its partner&nbsp;<b>AstraZeneca Plc</b>&nbsp;(NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (<i>ESMO21</i>) Congress 2021.</li>\n <li>The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).</li>\n <li>After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab&nbsp;reduced the risk of disease progression or death by 56%&nbsp;(hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.</li>\n <li>The 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.</li>\n <li>The confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).</li>\n <li>AstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.</li>\n <li>Also, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.</li>\n <li>Earlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.</li>\n <li>The analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.</li>\n <li><b>Price Action:</b>&nbsp;IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.</li>\n</ul>\n<p>Latest Ratings for IPHA</p>\n<table>\n <tbody>\n  <tr>\n   <th>Date</th>\n   <th>Firm</th>\n   <th>Action</th>\n   <th>From</th>\n   <th>To</th>\n  </tr>\n </tbody>\n <tbody>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Maintains</td>\n   <td></td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n </tbody>\n</table>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is Happening With Innate Pharma Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is Happening With Innate Pharma Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPHA":"Innate Pharma SA","AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2168575701","content_text":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.\nThe trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).\nAfter a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.\nThe 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.\nThe confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).\nAstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.\nAlso, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.\nEarlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.\nThe analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.\nPrice Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.\n\nLatest Ratings for IPHA\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nSep 2021\nSVB Leerink\nMaintains\n\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":884751294,"gmtCreate":1631936521218,"gmtModify":1632805210006,"author":{"id":"3571612770300673","authorId":"3571612770300673","name":"Rickyt089","avatar":"https://static.tigerbbs.com/4e75fb09fa53aa8d7db329d6599d40c1","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/884751294","repostId":2168575701,"repostType":4,"repost":{"id":"2168575701","pubTimestamp":1631916641,"share":"https://www.laohu8.com/m/news/2168575701?lang=&edition=full","pubTime":"2021-09-18 06:10","market":"us","language":"en","title":"What Is Happening With Innate Pharma Stock On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2168575701","media":"Benzinga","summary":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (N","content":"<ul>\n <li><b><a href=\"https://laohu8.com/S/IPHA\">Innate Pharma SA</a>&nbsp;</b>(NASDAQ: IPHA) stock is trading at a 52-week high as its partner&nbsp;<b>AstraZeneca Plc</b>&nbsp;(NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (<i>ESMO21</i>) Congress 2021.</li>\n <li>The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).</li>\n <li>After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab&nbsp;reduced the risk of disease progression or death by 56%&nbsp;(hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.</li>\n <li>The 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.</li>\n <li>The confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).</li>\n <li>AstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.</li>\n <li>Also, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.</li>\n <li>Earlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.</li>\n <li>The analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.</li>\n <li><b>Price Action:</b>&nbsp;IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.</li>\n</ul>\n<p>Latest Ratings for IPHA</p>\n<table>\n <tbody>\n  <tr>\n   <th>Date</th>\n   <th>Firm</th>\n   <th>Action</th>\n   <th>From</th>\n   <th>To</th>\n  </tr>\n </tbody>\n <tbody>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Maintains</td>\n   <td></td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n  <tr>\n   <td>Sep 2021</td>\n   <td>SVB Leerink</td>\n   <td>Upgrades</td>\n   <td>Market Perform</td>\n   <td>Outperform</td>\n  </tr>\n </tbody>\n</table>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is Happening With Innate Pharma Stock On Friday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is Happening With Innate Pharma Stock On Friday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical ...</p>\n\n<a href=\"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPHA":"Innate Pharma SA","AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/happening-innate-pharma-stock-friday-141041998.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2168575701","content_text":"Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021.\nThe trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).\nAfter a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab by 35% (HR of 0.65) compared to Imfinzi alone.\nThe 10-month progression-free survival (PFS) rate was 64.8% for the durvalumab plus oleclumab combo and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone.\nThe confirmed objective response rate (ORR) for Imfinzi plus oleclumab over Imfinzi alone (30% vs. 18%) and for Imfinzi plus monalizumab over Imfinzi alone (36% vs. 18%).\nAstraZeneca plans to start a registrational study with monalizumab plus durvalumab in the same indication.\nAlso, SVB Leerink maintained an Outperform on IPHA and raised its price target from $7 to $9.\nEarlier this month, analyst Daina Graybosch upgraded Innate to Outperform from Market Perform with a $7 price target.\nThe analyst was \"encouraged\" and said a \"strong signal\" would de-risk a large opportunity for monalizumab and change the narrative around Innate.\nPrice Action: IPHA shares are up 66.3% at $9.56 during the market session on the last check Friday.\n\nLatest Ratings for IPHA\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nSep 2021\nSVB Leerink\nMaintains\n\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform\n\n\nSep 2021\nSVB Leerink\nUpgrades\nMarket Perform\nOutperform","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5918379,"gmtCreate":1632014127768,"gmtModify":1634792735361,"authorId":3574906731000207,"author":{"id":3574906731000207,"authorId":3574906731000207,"name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884751294,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5919169,"gmtCreate":1632017597516,"gmtModify":1634792658780,"authorId":3579002978614578,"author":{"id":3579002978614578,"authorId":3579002978614578,"name":"Geoz88","avatar":"https://static.tigerbbs.com/40716588ae7919100620a5b5a9c48cac","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884751294,"type":1,"supId":5918379,"prevId":0,"content":"OK","text":"OK","html":"OK"},{"id":5927560,"gmtCreate":1632097519550,"gmtModify":1634791859444,"authorId":3574906731000207,"author":{"id":3574906731000207,"authorId":3574906731000207,"name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":884751294,"type":1,"supId":5918379,"prevId":0,"content":"[Strong][ShakeHands]","text":"[Strong][ShakeHands]","html":"[Strong][ShakeHands]"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":102,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}